Skip to main content

Table 2 The random effect model measures for efficacy and safety outcome and sensitivity analysis

From: Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis

  

OR (95% CI)

SUCRA

   

Primary Analysis

Outcome measure

A + C vs A

A + T vs A

A + T vs A + C

T vs A

A + T

A + C

A

T

 

stroke

0.69 (0.60,0.80)

0.66 (0.49,0.87)

1.16 (0.93,1.44)

0.80 (0.68,0.94)

61.00%

96.20%

0.70%

42.10%

 

ischemic stroke

0.68 (0.58,0.78)

0.66 (0.49,0.88)

1.16 (0.93,1.45)

0.78 (0.67,0.92)

63.60%

96.50%

0.90%

39%

 

vascular event

0.97 (0.63,1.49)

0.71 (0.36,1.40)

0.73 (0.43,1.23)

0.88 (0.46,1.70)

80.80%

36%

31.90%

51.40%

 

major bleeding

2.05 (1.11,3.77)

2.50 (1.25,4.99)

1.22 (0.62,2.39)

0.82 (0.40,1.68)

9.90%

25.40%

76.10%

88.60%

 

any bleeding

2.10 (1.22,3.59)

4.14 (2.00,8.55)

1.97 (1.21,3.22)

1.30 (0.66,2.55)

0.40%

38.00%

92.70%

68.90%

 

mortality

1.50 (0.93,2.41)

1.17 (0.76,1.82)

0.78 (0.46,1.32)

1.18 (0.83,1.67)

52.10%

14.30%

84.20%

49.30%

Sensitivity Analysis

ischemic stroke

0.70 (0.60,0.80)

0.76(0.65,0.88)

1.08(0.88,1.33)

 

70.60%

92.10%

0.80%

36.50%

 

major bleeding

1.83 (0.99,3.40)

3.0 (1.44,6.25)

1.64 (0.70,3.82)

4.30%

31.30%

74.90%

89.40%

  1. A aspirin, C clopidogrel, T ticagrelor
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us